# Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment

> **NCT05751759** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 31 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** Mitiperstat

## Key facts

- **NCT ID:** NCT05751759
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-20
- **Primary completion:** 2024-11-21
- **Final completion:** 2024-11-21
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2024-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05751759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05751759, "Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05751759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*